Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

Stopped early · Early Phase 1

Conditions studied: Pancreatic Cancer

In brief

This no treatment research study is being done to find a safe and an appropriate dose of antibody (protein) against tumor cells to best target the cancer in people with pancreatic cancer. To do this, this no-treatment research study will compare two doses of an antibody called hPAM4 IgG when combined with a radioactive element, Indium-111.

Key facts

Study ID
NCT00364364
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
People needed
2
Starts
2007-05-01
Expected to finish
2008-08-01
Last updated by the study team
2019-01-18

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.